Cancer Vaccine Partnering Agreements -





Published: November 2013 | Version: 4 | Pages: 365

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. 

   

  •  Trends in cancer vaccine partnering deals  
  •  Disclosed headlines, upfronts, milestones and royalties by stage of development 
  •  Cancer vaccine partnering contract documents 
  •  Top cancer vaccine deals by value 

 

   

 The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. 

   

 The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. 

   

 Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. 

   

 This report contains over 200 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. 

   

 The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma, big biotech and most active dealmakers in cabcer vaccine partnering. 

                      

 Chapter 3 provides a review of the leading cancer vaccine deals since 2007. Deals are listed by headline value, signed by big pharma and big biotech. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. 

   

 Chapter 4 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

   

 The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2007. This report comes with an additional appendix containing entire list of cancer vaccine dealmakers by Company A-Z, deal type and stage of development. 

                                                    

 In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products. 

   

 Report scope 

   

 Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide. 

   

 Cancer Vaccine Partnering Agreements includes:    

 

  •  Trends in cancer vaccine dealmaking in the biopharma industry since 2007  
  •  Analysis of cancer vaccine deal structure  
  •  Access to headline, upfront, milestone and royalty data  
  •  Access to over 200 cancer vaccine deal records  
  •  The leading cancer vaccine deals by value since 2007  
  •  Includes adjuvant and drug delivery deals and alliances since 2007 

    

 In Cancer Vaccine Partnering Agreements, the available deals are listed by: 

   

 Company A-Z 

 Headline value 

 Stage of development at signing 

 Deal component type 

 Specific oncology therapy target 

   

 Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

   

 The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals and contract documents for over 500 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following: 

   

 What are the precise rights granted or optioned? 

 What is actually granted by the agreement to the partner company? 

 What exclusivity is granted? 

 What is the payment structure for the deal? 

 How aresales and payments audited? 

 What is the deal term? 

 How are the key terms of the agreement defined? 

 How are IPRs handled and owned? 

 Who is responsible for commercialization? 

 Who is responsible for development, supply, and manufacture? 

 How is confidentiality and publication managed? 

 How are disputes to be resolved? 

 Under what conditions can the deal be terminated? 

 What happens when there is a change of ownership? 

 What sublicensing and subcontracting provisions have been agreed? 

 Which boilerplate clauses does the company insist upon? 

 Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? 

 Which jurisdiction does the company insist upon for agreement law? 

  

 Cancer Vaccine Partnering Agreements provides the reader with the following key benefits: 
    

 In-depth understanding of cancer vaccine deal trends since 2007 

 Access to headline, upfront, milestone and royalty data 

 Acces to the structure of cancer vaccine agreements with numerous real life case studies 

 Comprehensive access to over 200 actual cancer vaccine deals entered into by the world’s biopharma companies 

 Insight into the terms included in a cancer vaccine agreement, together with real world clause examples 

 Understand the key deal terms companies have agreed in previous deals           

 Undertake due diligence to assess suitability of your proposed deal terms for partner companies 

 
 


 


 

 

  

Executive Summary 

  

Chapter 1 – Introduction 

  

Chapter 2 – Trends in cancer vaccine dealmaking 

  

2.1. Introduction 

2.2. Cancer vaccine partnering over the years 

2.3. Big pharma cancer vaccine dealmaking activity 

2.3. Big biotech cancer vaccine dealmaking activity 

2.4. Most active in cancer vaccine partnering 

Advaxis 

ImmunoCellular Therapeutics 

National Cancer Institute 

Scancell 

GlaxoSmithKline 

2.5. Cancer vaccine partnering by deal type 

2.6. Cancer vaccine partnering by stage of development 

2.7. Cancer vaccine partnering by cancer indication 

2.8. Disclosed deal terms for cancer vaccine partnering 

2.8.1 Cancer vaccine partnering headline values 

2.8.2 Cancer vaccine deal upfront payments 

2.8.3 Cancer vaccine deal milestone payments 

2.8.4 Cancer vaccine royalty rates 

2.9. The anatomy of cancer vaccine partnering 

2.9. The anatomy of a cancer vaccine deal 

2.9.a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012 

2.9.b. Case study 2: University of Pennsylvania- VGX Pharmaceuticals: April 24, 2007 

  

Chapter 3 – Leading cancer vaccine deals 

  

3.1. Introduction 

3.2. Top cancer vaccine deals by value 

  

Chapter 4 – Cancer vaccine dealmaking directory 

  

4.1. Introduction 

4.2. Company A-Z 

3M 

A*STAR Bioprocessing Technology Institute 

Adamis Pharmaceuticals 

Adjuvantix 

AdnaGen 

Aduro BioTech 

Advaxis 

Affitech 

Agenus Bio 

Agilent Technologies 

Aldevron 

Alexis Biotech 

Alligator Bioscience 

Alnylam Pharmaceuticals 

AnGes MG 

Antigen Express 

Antigenics 

Argos Therapeutics 

Ariad Pharmaceuticals 

Arizona State University 

Astrimmune 

Australian Centre for Vaccine Development 

Avantogen Oncology 

AVAX Technologies 

Averion 

Bavarian Nordic 

Bayer Innovation 

Baylor College 

Baylor College of Medicine 

Baylor Research Institute 

Beijing Genomics Institute (BGI) 

Bellicum Pharmaceuticals 

Berlex 

Beth Israel Deaconess Medical Center 

Binex 

BinnoPharm 

Bio-Matrix Scientific 

BioAlliance Pharma 

Biomira 

BioSante Pharmaceuticals 

BioVest 

BioWa 

BN ImmunoTherapeutics 

Brigham Young University 

Bristol-Myers Squibb 

Broadvector 

Brown University 

BT Pharma 

Cadila Pharmaceuticals 

Cancer Research and Prevention Institute of Texas 

Cancer Research Institute 

Cancer Research Technology 

Cancer Research UK 

Cancer Research Wales 

Cancer Treatment Centers of America 

Cardiff University 

Catherex 

Cedars-Sinai Medical Center 

Cell Genesys 

Celldex Therapeutics 

Celltrion 

CG Therapeutics 

Champions Oncology 

ChemRar High-Tech Center 

City of Hope 

Clinipace Worldwide 

Cobra Biologics 

Colby Pharmaceuticals 

CSIRO 

CSL 

CureLab Oncology 

CureVac 

Cyto Pulse Sciences 

Cytos 

Daiichi Sankyo 

Dalton Pharma Services 

Dana-Farber Cancer Institute 

Delta-Vir 

Dendreon 

Department of Defense 

Diosynth 

Dynavax Technologies 

EMD Serono 

Encorium Group 

Entest BioMedical 

Favrille 

Federal Ministry of Education and Research (BMBF) 

Formatech 

Forska and Vax 

Fraunhofer Institute for Cell Therapy and Immunology 

Fred Hutchinson Cancer Research Center 

G-Con 

Galena Biopharma 

Genentech 

Generex Biotechnology 

Genetic Immunity 

GenoLac 

Genomic Expression 

German Cancer Research Center 

German Ministry for Education and Research 

GlaxoSmithKline 

Government of United Kingdom 

Gradalis 

Gynecologic Oncology Group 

Hawaii Biotechnology 

HemaCare 

HemispheRx Biopharma 

Henderson Morley 

Hokkaido University 

IBio 

Ichor Medical Systems 

IDIS Pharma 

Immatics Biotechnologies 

Immune Design 

ImmuneRegen BioSciences 

Immunicum 

ImmunoCellular Therapeutics 

Immunomedics 

Immunotope 

Immunovaccine 

ImmunoVaccine Technologies 

Immunovo 

ImmuRx 

Innate Pharma 

Inovio Biomedical 

Inovio Pharmaceuticals 

Institut Pasteur 

IRX Therapeutics 

ISSI-Strategy 

Jaiva Technologies 

Jantibody Therapeutics 

Japan Vaccine 

Jennerex 

John Hopkins University School of Medicines 

Johns Hopkins University 

JSC Binnopharm 

Juvaris BioTherapeutics 

KAEL-GemVax 

Karolinska Institute 

KellBenx 

Kirin Pharma 

Kyowa Hakko Kirin 

Ligand Pharmaceuticals 

Lipoxen 

London Genetics 

Ludwig Institute for Cancer Research 

LUNGevity Foundation 

MabVax Therapeutics 

Mary Crowley Cancer Research Center 

Maxcyte 

Mayo Clinic 

MD Anderson Cancer Center 

MDxHealth 

Medarex 

MediGene 

MedImmune 

Medivector 

Memorial Sloan Kettering Cancer Center 

Merck and Co 

Merck KGaA 

Merck Serono 

Merix Bioscience 

Methodist Hospital Research Institute 

MorphoSys 

Morphotek 

Mount Sinai School of Medicine 

Nanobiotix 

Natco Pharmaceuticals 

National Cancer Institute 

National Cancer Research Center 

National Institute of Allergy and Infectious Diseases 

National Institutes of Health 

National Research Council Canada 

NeoStem 

NewVac 

Northwest Biotherapeutics 

Norwegian Research Council 

Novartis 

Novavax 

Numoda 

NYU Langone Medical Center 

Ohio State University 

Omnimmune 

OncoMethylome 

OncoPep 

OncoSec Medical 

Oncotherapy Science 

Oncothyreon 

Oncovir 

Ono Pharmaceutical 

Onyvax 

Opsona Therapeutics 

Oxford BioMedica 

Oxford Immunotec 

PDS Biotechnology 

Pepscan Therapeutics 

Pevion 

Pfenex 

Pfizer 

Pharmexa 

Pharmsynthez 

Pique Therapeutics 

Pro-Cure Therapeutics 

Progenitor Cell Therapy 

Prometheus 

Prostate Cancer Foundation (PCF) 

PsiOxus Therapeutics 

Public Health Service 

Pulmotec 

Qiagen 

Radboud University Nijmegen Medical Centre 

Radiation Control Technologies 

Radient Pharmaceuticals 

Regen BioPharma 

Response Genetics 

Roche 

Rosetta Genomics 

RXi Pharmaceuticals 

Saint Savas Cancer Hospital 

Sanofi-Aventis 

SBI Biotech 

Scancell 

Scripps Research Institute 

Serum Institute of India 

SFJ Pharmaceuticals 

SOTIO 

Spectrum Pharmaceuticals 

Stellar Biotechnologies 

Stellar Pharmaceuticals 

Stemline Therapeutics 

Symphony Dynamo 

Systems Biology Worldwide 

Takeda Pharmaceutical 

TapImmune 

Tasly Pharmaceuticals 

Technomark Life Sciences 

Teva Pharmaceuticals 

The Regents of the University of California 

Therinject 

ToleRx 

Torrey Pines Institute for Molecular Studies 

Transgene 

UK Government 

UK Technology Strategy Board 

University of California, Davis 

University of Chicago 

University of Connecticut 

University of Copenhagen 

University of Florida 

University of Liege 

University of North Carolina 

University of Pennsylvania 

University of Pennsylvania School of Veterinary Medicine 

University of Pittsburgh 

University of Queensland 

University of Rouen 

University of Washington 

University of Western Ontario 

Uppsala University 

Vaccibody 

Vaccinogen 

Vanderbilt University 

Vaxil BioTherapeutics 

Vaximm 

VGX Pharmaceuticals 

Vibalogics 

Vinnova 

ViroMed 

Vivalis 

VLST Corporation 

Wilex 

Wistar Institute 

Wittycell 

Wuxi Apptec Laboratory Services 

Xencor 

4.3. By stage of development 

Discovery 

Formulation 

Marketed 

Phase I 

Phase II 

Phase III 

Preclinical 

Regulatory 

4.4. By deal type 

Asset purchase 

Bigpharma outlicensing 

Co-development 

Collaborative R&D 

Co-market 

Contract service 

Co-promotion 

CRADA 

Cross-licensing 

Development 

Distribution 

Equity purchase 

Evaluation 

Grant 

Joint venture 

Licensing 

Manufacturing 

Marketing 

Material transfer 

Option 

Research 

Settlement 

Sub-license 

Supply 

Technology transfer 

Termination 

Warranty 

4.5. By oncology therapy area 

Oncology 

4.6. By related technology 

Vaccines 

Adjuvant 

  

Chapter 5 –Partnering resource center 

  

5.1. Online partnering 

5.2. Partnering events 

5.3. Further reading on dealmaking 

  

Appendices 

Appendix 1 – Deal type definitions 

About Wildwood Ventures 

Current Partnering 

Current Agreements 

Recent report titles from CurrentPartnering 

Order Form – Therapy Reports 

Order Form – Reports